Safety, efficacy, and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population aged 5-49 years

Clinical Infectious Diseases

Volumn 39, Issue 7, 2004, Pages 920-927

  Belshe, Robert B ^a   Nichol, Kristin L ^b   Black, Steven B ^c   Shinefield, Henry ^c   Cordova, Julie ^d   Walker, Robert ^d   Hessel, Colin ^d   Cho, Iksung ^d   Mendelman, Paul M ^d  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c KAISER PERMANENTE   (United States)

^d MEDIMMUNE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; PLACEBO;

ACUTE RESPIRATORY TRACT DISEASE; ADOLESCENT; ADULT; ARTICLE; ASTHMA; BACTERIAL INFECTION; CHILD; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; GROUPS BY AGE; HEADACHE; HUMAN; INFLUENZA; INFLUENZA VACCINATION; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MYALGIA; NOSE CONGESTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SORE THROAT; VOMITING;

ADAPTATION, PHYSIOLOGICAL; ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; HUMANS; INFLUENZA VACCINES; MIDDLE AGED; VACCINES, ATTENUATED;

EID: 4744344803     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/423001     Document Type: Article

References (10)

1. Maassab HF, Francis T Jr, Davenport FM, et al. Laboratory and clinical characteristics of attenuated strains of influenza virus. Bull World Health Organ 1969; 41:589-94.
2. Belshe RB, Mendelman PM, Treanor J, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med 1998; 338:1405-12.
3. Belshe RB, Gruber WC, Mendelman PM, et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr 2000; 136:168-75.
4. Bergen R, Black S, Shinefield H, et. al. Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents. Pediatr Infect Dis J 2004; 23:138-44.
5. Nichol KL, Mendelman PM, Mallon KP, et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA 1999; 282:137-44.
6. Belshe RB, Gruber WC. Prevention of otitis media in children with live attenuated influenza vaccine given intranasally. Pediatr Infect Dis J 2000; 19(Suppl 5):S66-71.
7. Vaccines and Related Biological Products Advisory Committee. 17 December 2002.
8. Ashkenazi S, Vertruyen A, Aristegui J, et al. Comparison of safety and efficacy of a trivalent live attenuated, intranasal influenza vaccine (CAIV-T) with trivalent inactivated intramuscular vaccine (TIV) in children aged 6 to <72 months with a history of respiratory tract infections [abstract LB7]. In: Program and abstracts of the Pediatric Academic Societies' annual meeting (San Francisco). 2004.
9. Fleming D, Crovari P, Wahn U, et al. Comparison of safety and efficacy of a trivalent live attenuated intranasal influenza vaccine (CAIV-T) with trivalent inactivated intramuscular influenza vaccine (TIV) in children and adolescents aged 6 to <18 years with asthma [abstract LB20]. In: Program and abstracts of the Pediatric Academic Societies' annual meeting (San Francisco). 2004.
10. Bridges CB, Thompson WW, Meltzer MI, et al. Effectiveness and cost-benefit of influenza vaccination of healthy work adults: a randomized controlled trial. JAMA 2000; 284:1655-63.